

Fundamental Concepts of Sequencing

Carlos A. Saavedra-Matiz, MD
Newborn Screening Program
Wadsworth Center
New York State Department of Health


February 25, 2020
APHL-CDC





**Department
of Health**

**Wadsworth
Center**

DNA Replication Prior to Cell Division




Y-GA 98-647



The Central Dogma of Molecular Biology




Gene = DNA Instructions for A Specific RNA/Protein



POLYMERASE CHAIN REACTION

PCR Cycle - Step 1


Denaturation By Heat



- Heat denaturation (95 degrees C).
- Provides sufficient energy to break hydrogen bonds.

PCR Cycle - Step 2



Biotinylated Primer Pair
Anneals To Ends Of
Target Sequence



- Primer annealing 55-65 degrees C.
- Takes advantage of base complementarity.



POLYMERASE CHAIN REACTION




- Polymerization at 72 degrees C.
- Requires availability of *Thermus aquaticus* DNA polymerase (heat stable).

- After the first cycle, there are 2 copies of the original double helix.
- Continue cycling....





PCR: Exponential Amplification Of Targeted Sequence




POLYMERASE
CHAIN
REACTION

- And so on...for 30-35 cycles
- Result is billion-fold amplification of target.

Deoxyribonucleic Acid (DNA)




- A** Adenine
- T** Thymine
- C** Cytosine
- G** Guanine




https://upload.wikimedia.org/wikipedia/commons/d/d3/0322_DNA_Nucleotides.jpg

SEQUENCING: Determine the order of nucleotides in a DNA or RNA strand

Sanger





Separate DNA fragments by size
Detect fluorescent tag with a laser




Sanger Sequencing

① Reaction mixture

- ▶ Primer and DNA template
- ▶ DNA polymerase
- ▶ ddNTPs with flourochromes
- ▶ dNTPs (dATP, dCTP, dGTP, and dTTP)



③ Capillary gel electrophoresis separation of DNA fragments



④ Laser detection of flourochromes and computational sequence analysis






Fig 4A.

c.563A>G (p.Gln188Arg)





c.940A>G (p.Asn314Asp) Duarte



Molecular Analysis of GALC

- Reduce number of false positive screens
- Predict phenotype (?)
- Method:
 - Agarose gel for 2 common deletions
 - 30 kb & 7 kb
 - **Sequence all 17 exons and Promoter Region**

30 kb deletion




c.1586C>T (p.Thr529Met)
 acg > atg



c.1661 G>A (p.Arg554His) Heterozygous (female). Childhood cerebral & adult onset X-ALD





[Title: A Single Nucleotide Polymorphism in the T-Cell Receptor Excision Circle.](#)

Gans MD, Saavedra-Matiz CA, Bernstein L.

J Allergy Clin Immunol Pract. 2019 Aug 17. pii: S2213-2198(19)30720-2. doi: 10.1016/j.jaip.2019.08.014. [Epub ahead of print] No abstract available.

PMID:31430593



The Next Wave of DNA Sequencing

Buzzwords

- “Massively parallel” sequencing
- “High-throughput” sequencing
- “Ultra high-throughput” sequencing
- “Next generation” sequencing (NGS)
- “Second generation” sequencing

- **2005: 454 (Roche)**
- **2006: Solexa (Illumina)**
- **2007: ABI/SOLiD (Life Technologies)**
- **2010: Complete Genomics**
- **2011: Pacific Biosciences**
- **2010: Ion Torrent (Life Technologies)**
- **2015: Oxford Nanopore Technologies**




Next Generation Sequencing

- Utility
 - Sequence of a large gene
 - Sequence of several genes
 - Sequencing many people simultaneously

- Disorders
 - Cystic Fibrosis – large gene (44 exons, 10 -18 kb coding)
 - Severe Combined Immunodeficiency – 39 genes (55)



Steps in next-generation sequencing.




Illumina Sequencing by Synthesis Workflow

Library Preparation – prepares target DNA with indices and sequence adaptors




Illumina MiSeq Flow cell


3. Cluster Amplification



Amplification of target regions on flow cell



DNA sequencing – a single fluorescent nucleotide is added, an image is taken, and the process repeats




DNA sequence from each target is aligned

NGS Sequencing

- PCR amplify sample (opt.)
- Immobilize and amplify single molecules on a solid surface
- Reversible terminator sequencing with 4 color dye-labelled nucleotides



4 different images merged




6 cycles w/ base-calling



Top: CATCGT
Bottom: CCCCCC

Barcoding



Sample Barcoding


- Think of it as multiple Sanger sequencing reactions being imaged simultaneously.
- Saves time and money.

Molecular Barcoding (MBCs)

- Identify unique DNA molecules.
- Error correction.
- Copy-number variant (CNV) detection.


NYS Multi-Gene Panel

- Developing a multi-gene panel (VariantPlex assay).
 - Anchored Multiplex PCR (AMP)
- MBCs for detection of exon-level deletions/duplications



VariantPlex Assay

Mutation in primer-binding sequence
 Amplification by opposing primers is blocked, but successful by AMP



- Anchored Multiplex PCR (AMP)
- Minimum recommended DNA input 10 ng

Gene	Condition
<i>MCCC1</i>	(3-methylcrotonyl CoA carboxylase deficiency)
<i>MCCC2</i>	(3-methylcrotonyl CoA carboxylase deficiency)
<i>HBB</i>	(hemoglobinopathies)
<i>HBA1</i>	(alpha-thalassemia)
<i>HBA2</i>	(alpha-thalassemia)
<i>SLC22A5</i>	(primary carnitine deficiency)
<i>GALT</i>	(galactosemia)
<i>IDUA</i>	(mucopolysaccharidosis type 1)
<i>GAMT</i>	(guanidinoacetate methyltransferase deficiency)
<i>ACADVL</i>	(very long-chain acyl CoA dehydrogenase deficiency)
<i>ACADM</i>	(medium long-chain acyl CoA dehydrogenase deficiency)
<i>ETFA</i>	(multiple acyl-CoA carboxylase deficiency)
<i>ETFB</i>	(multiple acyl-CoA carboxylase deficiency)
<i>ETFDH</i>	(multiple acyl-CoA carboxylase deficiency)
<i>GAA</i>	(Pompe disease)
<i>ABCD1</i>	(X-Adrenoleukodystrophy)
<i>GALC</i>	(Krabbe disease)
<i>CPT2</i>	(carnitine palmitoyltransferase deficiency, type 2)
<i>HMGCL</i>	HMG
<i>HSD17B10</i>	2M3HBA
<i>AUH</i>	3MGA



39 – Gene Panel

CORO1A	CD3Z	ATM	LIG4	DOCK2
PRKDC	DCLRE1C	CHD7	NHEJ1	GATA2
TBX1	IL2RG	MTHFD1	RAC2	IGHM
ADA	IL7RA	MTR	CD3G	BTK
AK2	JAK3	RMRP	STAT5B	CD40LG
CD3D	RAG1	SLC46A1	ZAP70	WAS
CD3E	RAG2	DOCK8	PNP	DKC1
CD45	FOXN1	NBN	BLNK	


Genes involved in T-cell and B-cell deficiencies and syndromes

Adding 16




Sanger vs Next Generation Sequencing


Single Sequence vs. Parallel Sequence




Sanger sequencing




NGS sequencing



Targeted Next-generation Sequencing Overview



NGS Analysis Workflow (Pipeline)



Pathogenic

NM_000033.3(ABCD1):c.1390C>T
(p.Arg464Ter) – Heterozygous

NM_000033.3(ABCD1):c.1771C>T
(p.Arg591Trp) - Heterozygous

VOUS

NM_000033.3(ABCD1):c.1780+4G>A -
Heterozygous

Two NGS Platforms Used for SCID Sequencing



Illumina MiSeq –
TruSeq Custom
Amplicon/ AS panel




ThermoFisher Chef/S5
AmpliSeq (AS) panel

Types of Variants

Effects of single base mutations in DNA Code				
Mutation type	<i>silent</i>	<i>missense</i>	<i>nonsense</i>	<i>readthrough</i>
New amino acid	Gly	His	Stop	Leu
Change in DNA	GGA	CAU	UAA	UUA
Triplet code of original DNA sequence	<p>ATGGGCATT CGT AGC TAT CCA TAAAAATATATA...</p> <p>Met Gly Ile Arg Ser Tyr Pro Stop</p>			

Dried Blood Spot (DBS) “Guthrie” Card


- S&S® 903™ Cotton Paper
- 3.1 mm DBS ~ 3.1 uL whole blood.
- Benefits:
 - Rapid absorption (~ 10 seconds)
 - Easy transportation
 - Blood constituents “easily” eluted
 - Typeable DNA from 3-15 years.
- > 2500 articles in PubMed
- > 14 Million Google “hits”



6 Puncture heel. Wipe away first blood drop with sterile gauze pad. Allow another LARGE blood drop to form.



8 Fill remaining circles in the same manner as step 7, with successive blood drops. If blood flow is diminished, repeat steps 5 through 7. Care of skin puncture site should be consistent with your institution's procedures.



7 Lightly touch filter paper to LARGE blood drop. Allow blood to soak through and completely fill circle with SINGLE application to LARGE blood drop. (To enhance blood flow, VERY GENTLE intermittent pressure may be applied to area surrounding puncture site). Apply blood to one side of filter paper only.



9 Dry blood spots on a dry, clean, flat non-absorbent surface for a minimum of four hours.



10 Mail completed form to testing laboratory within 24 hours of collection.

Information provided by The New York State Department of Health.

Schleicher & Schuell Inc. • 10 Optical Avenue • Keene N.H. 03431 USA • Tel. (603) 352-3810 • Fax (603) 355-6524 • Internet: <http://www.s-and-s.com> • e-mail: solutions@s-and-s.com
 Schleicher & Schuell GmbH • P.O. Box 4, D-37502 Dassel • Germany • Tel. 49-5561-791-0 • Fax 49-5561-791536 • Internet: <http://www.s-und-s.de> • e-mail: filtration@s-und-s.com
 Other Subsidiaries of Schleicher & Schuell include the Netherlands, Switzerland, France, Belgium, Hungary, Italy and Great Britain



Department
of Health

Wadsworth
Center

Clin Chem 59:7; 1045-1051 (2013)

Cost-Effective and Scalable DNA Extraction Method from Dried Blood Spots.

Saavedra-Matiz CA, Isabelle JT, Biski CK, Duva SJ, Sweeney ML, Parker AL, Young AJ, Diantonio LL, Krein LM, Nichols MJ, Caggana M.

Newborn Screening Program, Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, NY.

Abstract

BACKGROUND: Dried blood spot (DBS) samples have been widely used in newborn screening (NBS) for the early identification of disease to facilitate the presymptomatic treatment of congenital diseases in newborns. As molecular genetics knowledge and technology progresses, there is an increased demand on NBS programs for molecular testing and a need to establish reliable, low-cost methods to perform those analyses. Here we report a flexible, cost-efficient, high-throughput DNA extraction method from DBS adaptable to small- and large-scale screening settings. **METHODS:** Genomic DNA (g.DNA) was extracted from single 3-mm diameter DBS by the sequential use of red cell lysis, detergent-alkaline, and acid-neutralizing buffers routinely used in whole blood and plant tissue DNA extractions. We performed PCR amplification of several genomic regions using standard PCR conditions and detection methods (agarose gel, melting-curve analysis, TaqMan-based assays). Amplicons were confirmed by BigDye® Terminator cycle sequencing and compared with reference sequences. **RESULTS:** High-quality g.DNA was extracted from hundreds of DBS, as proven by mutation detection of several human genes on multiple platforms. Manual and automated extraction protocols were validated. Quantification of g.DNA by Oligreen® fluorescent nucleic acid stain demonstrated a normal population distribution closely corresponding with white blood cell counts detected in newborn populations. **CONCLUSIONS:** High-quality, amplifiable g.DNA is extractable from DBSs. Our method is adaptable, reliable, and scalable to low- and high-throughput NBS at low cost (\$0.10/sample). This method is routinely used for molecular testing in the New York State NBS program.

Clin Chem 59:7; 1011-1013 (2013)

Editorials

Newborn Screening by Sequence and the Road Ahead.

Sondheimer N.

Department of Pediatrics, University of Pennsylvania, and Section of Biochemical Genetics, Children's Hospital Philadelphia, Philadelphia, PA.



**Department
of Health**

**Wadsworth
Center**

Molecular Testing in Newborn Screening

- **Primary** molecular test
- When no other assay is available
 - Severe Combined Immunodeficiency (**SCID**)
 - Spinal Muscular Atrophy (**SMA**)
- **Second tier** molecular test
- **Increase sensitivity or specificity of primary assay**
 - Cystic Fibrosis (CF), Krabbe, **Pompe**, **MPSI**, etc.
- **Clarify an ambiguous result**
 - Hemoglobinopathies
- **Supplemental “Just in Time” assay**
 - Galactosemia, **X-ALD** (if not Pathogenic Variants > other PBD), MCAD



Second/Third tier DNA Sequencing Clinical Assessment vs Supplemental

- **Pompe/MPS I/Krabbe/Cystic Fibrosis: Sanger sequencing of gene**
 - Reduces referrals – contributes to the clinical assessment
 - Can provide information on classic infantile forms phenotype
 - Report detected

- **ALD: full sequencing of ABCD1 gene**
 - Not intended to reduce referrals – supplemental
 - Determine if females are ALD carriers
 - Determine if males have mutation
 - if no mutation, consider other PGD
 - For ABCD1, genotype (nor marker concentrations) do not correlate with phenotype!!



Tools to Classify DNA Sequence Variants

- Review of primary literature
- Databases
 - GnomAD - <http://gnomad.broadinstitute.org/>
 - ClinVar - <https://www.ncbi.nlm.nih.gov/clinvar/>
 - ExAC Browser - <http://exac.broadinstitute.org/>
 - Gene specific databases
 - [MPS-1](#)
 - <http://mps1-database.org/>
 - [ALD](#)
 - <http://www.x-ald.nl/>
 - [Pompe](#)
 - https://www.erasmusmc.nl/klinische_genetica/research/ijnen/pompe_center/moleculaire_aspecten/?lang=en



Searching gnomAD Database for Your Variant

gnomAD – Genome Aggregation Database

gnomAD browser About Downloads Terms Contact Jobs FAQ

This is a new version of the gnomAD browser. The old version is available at <http://gnomad-old.broadinstitute.org>

ABCD1 ATP-binding cassette, sub-family D (ALD), member 1 Current Dataset:

Ensembl gene ID: [ENSG00000101986](#)
 Ensembl transcript ID: [ENST00000218104 \(canonical\)](#)
 Number of variants: 1,028 (including filtered variants)
 UCSC Browser: [X152990324-153010217](#)
 GeneCards: [ABCD1](#)
 OMIM: [300371](#)

Gene Constraint

Category	Exp. no. variants	Obs. no. variants	Constraint metrics
Synonymous	154.8	146	Z = 0.55 $\frac{o/e = 0.94}{(0.82 - 1.08)}$ 0 1
Missense	338.8	235	Z = 2.05 $\frac{o/e = 0.69}{(0.62 - 0.77)}$ 0 1
LoF	19.7	0	pLI = 1 $\frac{o/e = 0}{(0.00 - 0.15)}$ 0 1

exome genome

Include: CDS UTR Non-coding transcript

Show transcripts Mean per tissue ClinVar pathogenic and likely pathogenic variants (80) gnomAD v2.1 (784) Bins All variants

Viewing in table <https://gnomad.broadinstitute.org/gene/ENSG00000101986>


gnomAD – 125,748 exome sequences and 15,708 whole-genome sequences from 141,456 unrelated individuals



Department of Health

Wadsworth Center

gnomAD Variant Search Results for ALD (*ABCD1* gene)



LoF only
 Missense only
 Synonymous only
 Other only

Include filtered variants
 SNPs
 Indels

[Search variant table](#)

[Export variants to CSV](#)

† denotes a consequence that is for a non-canonical transcript

Variant ID	Source	Consequence	Annotation	Flags	Allele Count	Allele Number	Allele Frequency	Number of Homozygotes	Number of Hemizygotes
X-153005554-A-G	E	c.1497A>G(p.=)	synonymous		1	181555	5.508e-6	0	0
X-153005575-A-T	E	c.1518A>T(p.=)	synonymous		3	182241	1.646e-5	0	1
X-153005578-C-T	E G	c.1521C>T(p.=)	synonymous		5	204151	2.449e-5	0	2
X-153005583-A-G	E	p.Asn509Ser	missense		1	182301	5.485e-6	0	0
X-153005590-C-T	E	c.1533C>T(p.=)	synonymous		5	182133	2.745e-5	0	0
X-153005593-C-G	E	c.1536C>G(p.=)	synonymous		1	182294	5.486e-6	0	0
X-153005596-G-A	E G	c.1539G>A(p.=)	synonymous		2	204350	9.787e-6	0	1
X-153005599-C-T	E	c.1542C>T(p.=)	synonymous		3	182341	1.645e-5	0	1
X-153005605-G-A	E G	c.1548G>A(p.=)	synonymous		19244	204205	9.424e-2	636	7522
X-153005608-C-T	E	c.1551C>T(p.=)	synonymous		2	182410	1.096e-5	0	0
X-153005610-G-A	E	p.Arg518Gln	missense		1	182400	5.482e-6	0	0
X-153005624-C-A	G	p.Leu523Ile	missense		1	21901	4.566e-5	0	1
X-153005638-C-T	E G	c.1581C>T(p.=)	synonymous		44	204577	2.151e-4	0	13
X-153005639-G-A	E G	p.Gly528Ser	missense		8	204648	3.909e-5	0	1
X-153005645-G-A	E	p.Val530Met	missense		1	182794	5.471e-6	0	0
X-153005654-A-C	E	p.Lys533Gln	missense		1	182895	5.468e-6	0	0
X-153005668-G-C	E	p.Gln537His	missense		2	182857	1.094e-5	0	1
X-153005669-C-T	E	p.Arg538Cys	missense		1	182791	5.471e-6	0	0
X-153005670-G-A	E	p.Arg538His	missense		1	182755	5.472e-6	0	1

<https://gnomad.broadinstitute.org/gene/ENSG00000101986>



Department of Health

Wadsworth Center

gnomAD Variant Population Frequency Results

[Request additional information](#)

Annotations

This variant falls on 3 transcript(s) in 2 gene(s).

missense

- ABCD1**
 - ENST00000218104 *
 HGVS: p.Arg518Gln
 Polyphen: *probably_damaging*
 SIFT: *deleterious*
 - ENST00000443684
 HGVS: p.Arg186Gln
 Polyphen: *probably_damaging*
 SIFT: *deleterious*

intron


- U52111.14**
 - ENST00000434284 *

Population Frequencies

Population	Allele Count	Allele Number	Number of Homozygotes	Number of Hemizygotes	Allele Frequency
European (non-Finnish)	1	81371	0	0	0.00001229
African	0	13154	0	0	0.000
Latino	0	27317	0	0	0.000
Ashkenazi Jewish	0	7394	0	0	0.000
East Asian	0	13845	0	0	0.000
European (Finnish)	0	15907	0	0	0.000
Other	0	4506	0	0	0.000
South Asian	0	18906	0	0	0.000
Total	1	182400	0	0	0.00005482


Include: Exomes Genomes

Genotype Quality Metrics




All Variant Carriers Genotype Quality Exomes Genomes

Age Distribution



Heterozygotes Homozygotes

Site Quality Metrics



SiteQuality (2388) Exomes Genomes

Note: These are site-level quality metrics; they may be unpredictable for multi-allelic sites.



ClinVar Results of ALD Variant

ClinVar – Database with Clinical and Genomic Information

NCBI Resources How To Sign in to NCBI

ClinVar Search ClinVar for gene symbols, HGVS expressions, conditions, and more [Advanced](#) [Help](#)

Home About Access Help Submit Statistics FTP

NEW [Click here](#) to see the new Variation Report design!

NM_000033.3(ABCD1):c.1553G>A (p.Arg518Gln)

Variation ID: **92317**
 Review status: **★ ★ ☆ ☆** criteria provided, multiple submitters, no conflicts

Interpretation [?](#) Go to: [📧](#) [🔍](#)

Clinical significance: [Pathogenic](#)
 Last evaluated: Apr 26, 2017
 Number of submission(s): 2
 Condition(s): [Adrenoleukodystrophy](#) [[MedGen](#) - [Orphanet](#) - [OMIM](#)]
[See supporting ClinVar records](#) [🔗](#)

Allele(s) [?](#) Go to: [📧](#) [🔍](#)

NM_000033.3(ABCD1):c.1553G>A (p.Arg518Gln)

Allele ID: 98228
 Variant type: single nucleotide variant
 Cytogenetic location: Xq28
 Genomic location:

- ChrX: 153740156 (on Assembly GRCh38)
- ChrX: 153005610 (on Assembly GRCh37)

 Protein change: R518Q
 HGVS:

- NG_009022.2:g.20289G>A
- NM_000033.3:c.1553G>A
- NP_000024.2:p.Arg518Gln

[...more](#)
 Links:

- ClinGen: [CA278403](#)
- UniProtKB: [P33897#VAR_000070](#)
- dbSNP: [rs398123102](#)

 NCBI 1000 Genomes Browser: [rs398123102](#)
 Molecular consequence: NM_000033.3:c.1553G>A: missense variant [Sequence Ontology [SO:0001583](#)]
 Allele frequency:

- Exome Aggregation Consortium (ExAC) 0.00001
- The Genome Aggregation Database (gnomAD), exomes 0.00001

1 Affected gene [⌵](#)
ATP binding cassette subfamily D member 1 (ABCD1) [Gene - OMIM - Variation Viewer]
[Haploinsufficiency - Sufficient evidence for dosage pathogenicity \(Apr 26, 2012\)](#)
[Triplosensitivity - No evidence available \(Apr 26, 2012\)](#)
[🔍 Search ClinVar for variants within ABCD1](#)
[🔍 Search ClinVar for variants including ABCD1](#)

Variant frequency in dbGaP [?](#) [⌵](#)
 No dbGaP data has been submitted for this variant.

Browser views [⌵](#)
[RefSeqGene](#)
[Variation Viewer \[GRCh38 - GRCh37\]](#)
[UCSC \[GRCh38/hg38 - GRCh37/hg19\]](#)

Related information [⌵](#)
[dbSNP](#)
[Functional Class](#)
[Gene](#)
[MedGen](#)
[OMIM](#)
[PMC](#)
[PubMed](#)
[Related genes \(specific\)](#)

<https://www.ncbi.nlm.nih.gov/clinvar/variation/92317/>



Department of Health

Wadsworth Center

Challenges of Sequencing

- ❑ **Major Challenge: Determining pathogenicity**
- ❑ **ACMG defined 5 categories to classify variants:**
 - **Known pathogenic**
 - **Likely to be pathogenic**
 - **Unknown significance**
 - **Likely to be benign**
 - **Benign**
- ❑ **Knowledge accruing daily, however the medical impact of most variants is unknown**



Acknowledgments

New York State Newborn Screening Program

Michele Caggana, ScD, FACMG

Colleen Stevens, PhD

Denise Kay, PhD

Robert Sicko, BS

DNA Lab Group

New York State Department of Health

Wadsworth Center

New York State Specialty Care Centers



Mi familia.